drugset

drugset / Trial / NCT00889421

Apremilast in the Treatment of Uveitis

NCT00889421 ↗

Phase 1/2 Terminated 3 enrolled Oregon Health and Science University Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Timeline

Start: 2009-11
Primary completion: 2011-06
Completion: 2011-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apremilast	Small molecule	30 mg	Oral

Indications